Adaptive Biotechnologies Files 8-K

TL;DR

ADPT filed an 8-K on June 11th for events on June 7th, including shareholder votes.

AI Summary

Adaptive Biotechnologies Corporation filed an 8-K on June 11, 2024, reporting on matters submitted to a vote of security holders and other events that occurred on June 7, 2024. The filing details the company's principal executive offices located at 1165 Eastlake Avenue East, Seattle, Washington, 98109.

Why It Matters

This 8-K filing indicates that Adaptive Biotechnologies Corporation has submitted matters for a vote by its security holders and is reporting on other significant corporate events.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of corporate events and shareholder votes, not indicating any immediate financial distress or significant operational change.

Key Players & Entities

• Adaptive Biotechnologies Corporation (company) — Registrant
• June 11, 2024 (date) — Filing Date
• June 7, 2024 (date) — Earliest Event Date
• 1165 Eastlake Avenue East, Seattle, Washington, 98109 (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — ch registered Common stock, par value $0.0001 per share ADPT The Nasdaq Stock Mar

Filing Documents

• adpt-20240607.htm (8-K) — 61KB
• 0000950170-24-071913.txt ( ) — 173KB
• adpt-20240607.xsd (EX-101.SCH) — 24KB
• adpt-20240607_htm.xml (XML) — 5KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On June 7, 2024, Adaptive Biotechnologies Corporation (the " Company ") held its annual meeting of shareholders (the " Annual Meeting ") pursuant to notice duly given. Three proposals were presented for voting: Proposal 1: election of two Class II directors to the Board of Directors (Peter Neupert and Michelle Griffin); Proposal 2: an advisory request concerning compensation for the Company's 2023 named executive officers; and, Proposal 3: ratification of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024. Each of the proposals was described in detail in the Company's definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 26, 2024. A quorum of the shareholders voted by the conclusion of the Annual Meeting. The final results of the voting are set forth below. Proposal 1: Election of Class II Directors Peter Neupert Votes Submitted As % of Proposal Votes Broker Non Vote For 82,704,811 69.15 % 14,893,022 Against - - Withhold/Abstain 36,895,764 30.85 % Michelle Griffin Votes Submitted As % of Proposal Votes Broker Non Vote For 99,854,001 82.93 % 14,080,001 Against - - Withhold/Abstain 20,559,595 17.07 % Proposal 2: Advisory Vote Concerning the 2023 Compensation of the Company's Named Executive Officers Votes Submitted As % of Proposal Votes Broker Non Vote For 103,594,016 86.00 % 14,033,887 Against 15,410,744 12.79 % Withhold/Abstain 1,454,950 1.21 % Proposal 3: Ramification of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm for the Year Ending December 31, 2024 Votes Submitted As % of Proposal Votes Broker Non Vote For 133,954,711 99.60 % 0 Against 339,767 0.25 % Withhold/Abstain 199,119 0.15 %

01 Other Events

Item 8.01 Other Events. On June 10, 2024, NASDAQ notified the Company that it is in compliance with Listing Rule 5605(c)(2) (the " Rule "). Specifically, the Company's appointment of Peter Neupert to its audit committee in July of 2023 resolved the deficiency under the Rule previously noted following the departure of former Company director Leslie Trigg.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Adaptive Biotechnologies Corporation Date: June 11, 2024 By: /s/ Kyle Piskel Kyle Piskel Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR